John Parkinson

A secondary analysis of a randomized trial points to limited benefits on the microbiota.

Boar’s Head is recalling its liverwurst product as well as other deli meats due to concerns around contamination.

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

The antiviral began its development as a multidrug-resistant therapy for people with HIV, and has since been studied as PrEP intervention, with many now calling for it to be made widely available for mass distribution.

A pilot study looked at offering this form of pre-exposure prophylaxis (PrEP) to a select population to see if it could be effective in preventing sexually transmitted infections (STIs).

A study finds clinically-relevant sub-phenotypes can be reproducibly, and could lead to patient stratification and treatment.

CDC reports 2 deaths so far, and several more people sickened across multiple states.

Participants of the phase 3 trial for the Pfizer and Valneva vaccine candidate, VLA15, received their immunizations and everyone will be observed through next year’s Lyme disease season.

A large study from the Veterans Affairs shows an association between being unvaccinated and a greater incidence rate of Long COVID.

The second episode in our series looks to address clinical management in a time when antimicrobial resistance appears to be growing.

The disconnect between evolving science and medical communication has left people confused about how to interpret public health information, and provided an opportunity for vaccine deniers and politicians to give disinformation on COVID-19.

The individuals who worked in an egg layer facility in Colorado were confirmed to have H5N1 and they have reported mild symptoms without hospitalizations.

The company acquired rights from CureVac to develop vaccines for influenza and COVID-19 using the mRNA platform.

An outside physician who was working at 3 hospitals in the Portland, Oregon area did not follow infection prevention protocols, leaving patients potentially exposed to bloodborne infections.

The Centers for Disease Control and Prevention (CDC) and the National Foundation for Infectious Diseases (NFID) both weigh in on the evolving summer COVID-19 season, and strategies for prevention.

This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.

The company, Al-Safa US, is recalling approximately 2010 pounds of imported frozen ready-to-eat chicken products.

As of July 2nd, 2024, 449 people have been sickened and 124 people hospitalized.

The report comes from Colorado, and public health officials have not yet identified the source of transmission.

The $176 million award is for late-stage development of widespread immunization capability against H5 (avian) influenza, should such vaccines be needed.

The case occurred to a man in Colorado who had direct contact with cattle and state public health officials offer details on the patient as well as the risk to the public.

The Johnson & Johnson therapy, bedaquiline (Sirturo), was given the nod in both the United States and Europe for mycobacterium tuberculosis resistant to at least rifampicin and isoniazid.

A new study shows a greater likelihood of contracting this foodborne illness associated with a local area's socioeconomic vulnerability index (SVI) rank level, and reinforces the importance of addressing disparities in food safety.

Biopharmaceutical company, Dynavax, is comparing its investigational immunization against a FDA-approved vaccine.

The federal agency says everyone 75 years of age and older should receive the RSV vaccine.

A retracted paper that erroneously claimed the measles, mumps and rubella (MMR) vaccine caused autism has repercussions still being felt today around topics such as vaccination, misinformation and disinformation, and measles incidence rates.

The WHO reports the variant, clade I MPXV, has been circulating in a region within the Democratic Republic of Congo since last year.

Those individuals who received older versions of vaccines did not see significantly reduced risks of severe COVID-19 outcomes.

In a small study, recurrent Clostridioides difficile infection (CDI) therapy, Rebyota, was durable in a majority of patients who were exposed to non-CDI antibiotics.

Berkeley Heights, NJ-based biopharmaceutical company, CorMedix, is working towards an expanded indication for its DefenCath product, for the prevention of these healthcare-associated infections.